{'fraction_non_alphanumeric': 0.017793594306049824, 'fraction_numerical': 0.0, 'mean_word_length': 5.752, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
RENIN INHIBITION: IMMUNOLOGICAL PROCEDURES AND RENIN INHIBITOR PEPTIDES

Summary— Renin inhibitors represent an alternative to angiotensin‐converting enzyme inhibitors (ACEI) for the treatment of hypertension. They inhibit the renin‐angiotensin system at its first and rate limiting step, the renin‐angiotensinogen reaction. Passive administration of angiotensinogen or renin antibodies lowers blood pressure in primates to the same extent as ACEI. Chronic active immunization against renin decreases blood pressure markedly in normotensive marmosets. Renin can be inhibited by peptides derived from its prosegment. The design of compounds based on pepstatin and on angiotensinogen sequence has led to very potent and specific human renin inhibitors. Such inhibitors are active by the IV route in primates but still lack of good oral activity.